
Pharmacokinetics and safety of a single dose of the novel LAMA/LABA fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler, formulated using co-suspension delivery technology, in Japanese healthy subjects
Keywords: GFF MDI; Chronic obstructive pulmonary disease; Co-suspension delivery technology; LAMA/LABA; Pharmacokinetics; AE; adverse event; AUC0-12; area under the curve from 0 to 12â¯h; AUC0-t; area under the curve from 0 to time of the last measurable plasm